Clinical trials: Recurrent Ovarian Epithelial Cancer
Ovarian Cancer
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.
- Trial name
- NCT00345540
- Testing
- NOV-002, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cellectar Biosciences, Inc.
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or…
- Trial name
- NCT02983799
- Testing
- OLAPARIB
- Where
- 47 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Ovarian Cancer Recurrent
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer.
- Trial name
- MAIA-ovarian (NCT06888921)
- Testing
- COM701, Normal Saline
- Where
- 27 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Compugen Ltd
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I clinical trial studies the side effects of sirolimus and NY-ESO-1 protein with MIS416 in treating patients stage II-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IIA Fallopian Tube Cancer
- Trial name
- NCT02833506
- Testing
- Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Recurrent Ovarian Epithelial Cancer
Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer
Phase I trial to study the effectiveness of a tumor cell vaccine and interferon gamma in patients with refractory epithelial ovarian cancer.
- Trial name
- NCT00004032
- Testing
- ALVAC-hB7.1, recombinant interferon gamma, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Platinum-sensitive Relapsed Ovarian Cancer
Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus chemotherapy and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib (PARP inhibitor)and…
- Trial name
- NCT06446206
- Testing
- Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
- Volunteers
- 22 people
- Sponsor
- The First Hospital of Jilin University
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Recurrent Ovarian Carcinoma
Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity
The proposed study is a prospective cohort study incorporating patients with first recurrence ovarian or primary peritoneal cancer who will receive intraperitoneal chemotherapy in conjunction with whole abdomen radiation.
- Trial name
- WAR (NCT00942838)
- Testing
- Cisplatin, Whole Abdomen Radiotherapy
- Where
- United States
- Sponsor
- University of Utah
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002508
- Testing
- carboplatin, etoposide, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Temple University
Ovarian Cancer, Ovarian Clear Cell Carcinoma
Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma
Primary Objective: The primary objective of this study is to evaluate the efficacy and safety of liposomal irinotecan in combination with sintilimab and anlotinib in patients with recurrent or persistent ovarian clear cell…
- Trial name
- NCT07239622
- Testing
- Treatment
- Volunteers
- 36 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Relapsed Ovarian Cancer
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
This study aims to carry out a multi-center, randomized controlled study on patients with recurrent ovarian cancer after PARPi maintenance, to explore the clinicopathological and molecular characteristics of patients with…
- Trial name
- NCT05607329
- Testing
- Secondary cytoreduction, Chemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Ovarian Cancer
Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma
Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate.
- Trial name
- EPOCA (NCT07540403)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Extragonadal Germ Cell Tumor, Ovarian Cancer
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
- Trial name
- NCT00453310
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003080
- Testing
- endocrine-modulating drug therapy, melphalan, mitoxantrone hydrochloride
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
- Trial name
- NCT02537444
- Testing
- Acalabrutinib, acalabrutinib and pembrolizumab combination
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Acerta Pharma BV
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
This pilot phase I trial studies how well dasatinib works together with paclitaxel and carboplatin in treating patients with stage III, stage IV, or endometrial cancer that has come back after a period of improvement.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT01440998
- Testing
- Carboplatin, Dasatinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Ovary Neoplasm, Ovarian Cancer
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian…
- Conditions
- Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
- Trial name
- NCT06305299
- Testing
- iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Low-grade Serous Ovarian Carcinoma, Recurrent Invasive Borderline Serous Ovarian Cancer
Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
The purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in Italy.
- Trial name
- MITO 22 (NCT02408536)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Cancer
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
This study is a multi - center, single - arm, open - label, phase Ib/II clinical trial for dose exploration and efficacy expansion.
- Trial name
- NCT06990516
- Testing
- SHR-A1811, Carboplatin, Oxaliplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tongji Hospital
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)